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Abstract
Treatment of rats suffering from florid chronic progressive systemic arthritis or from chronic
remitting/relapsing encephalomyelitis with autologous bone marrow transplantation (BMT) is
highly effective. This finding was unexpected as the genotype of the bone marrow largely
determines the susceptibility of both spontaneous and induced autoimmune diseases in
rodents. The success of autologous stem-cell transplantation depends on the completeness
of eradication of the effectors of autoimmune disease, in other words activated and memory
T lymphocytes. The reviewed experimental data, when translated to the clinic, indicate that
the patients should be subjected to a conditioning regimen that induces maximal lympho-
ablation and that the autologous transplant has to be T-cell depleted.
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Introduction
The pivotal role of the haematopoietic system was revealed
by investigations in haematopoietic chimeras between
rodent strains that are susceptible or resistant to various
autoimmune diseases (for review [1]). Whether these
chimeric animals develop autoimmune disease is generally
dictated by the genotype of the bone marrow, which led to
the hypothesis that the underlying defect resides in the
haematopoietic stem cell [2]. These experiments were per-
formed with many different models of autoimmune disease,
but there is no consensus regarding which models are rep-
resentative of the corresponding human disease.
The animal models of autoimmune disease are of two
distinct types: the hereditary or spontaneous forms and the
induced forms. In diseases of the first category, the symp-
toms develop with age in most or all of the members of a
particular inbred strain of rodents. These models include
systemic lupus erythematosus-like syndromes in mice,
insulin-dependent diabetes mellitus in mice and rats, and a
complex syndrome of arthritis/colitis/dermatitis in human
leucocyte antigen-B27 transgenic rats. Genetic factors
dominate in the pathogenesis of these diseases. The
autoimmune diseases of the second category do not
develop spontaneously, but require induction by immuniza-
tion with specific tissues (eg brain in the case of experimen-
tal allergic encephalomyelitis [EAE], which serves as model
of multiple sclerosis), with tissue components like collagen
(ie collagen-induced arthritis), or with bacterial antigens like
Mycobacteria tuberculosis (adjuvant arthritis [AA]). These
diseases can only be induced in specific strains of rodents.
Susceptibility and resistance to induction are largely
genetically determined, as demonstrated by cross-breeding,
but environmental influences are also involved.Arthritis Research    Vol 2 No 4 van Bekkum
The aetiology of human autoimmune diseases is multifac-
torial, the dominant contributors being genetic as well as
environmental. Thus, it is likely that the inducible autoim-
mune diseases represent the more realistic models for
preclinical investigations. The curative potential of autolo-
gous BMT was demonstrated in rats with induced arthritis
and induced encephalomyelitis. Other animal models have
not been explored so far.
Treatment of full-blown autoimmune diseases
with BMT
The experiments in haematopoietic chimeras had a
logical sequel in attempts to cure animals with overt
autoimmune diseases by replacing their bone marrow
with that from an allogeneic donor of a normal or a nonin-
ducible strain. The myeloablation and lymphoablation
that is required to achieve complete allogeneic
chimerism is also highly effective in reducing the burden
of autoreactive lymphocytes. Accordingly, allogeneic
BMT after high-dose total body irradiation (TBI) was
found to cure hereditary as well as inducible forms of
autoimmune disease. Following these publications (for
review [3]), the hospital records of long-term survivors of
allogeneic BMT, as treatment for an haematological
malignancy or aplastic anaemia, were searched for
patients with coexisting autoimmune diseases at the time
of the transplantation. A total of 21 patients were identi-
fied, comprising a wide range of autoimmune diseases,
which went into complete remission in all of these
patients [4,5]. Obviously, aplastic anaemia is itself an
autoimmune disease that has been treated succesfully
with allogeneic BMT for several decades.
On the other hand, the prevailing concepts at that time did
not foster the idea of using autologous BMT for treating
autoimmune diseases, because of the dominant influence
of the genotype of the bone marrow on susceptibility to
experimental autoimmune disease. It was therefore a com-
plete surprise that animals suffering from AA responded
just as well to autologous and to syngeneic BMT as they
did to grafting with allogeneic bone marrow [6••].
The substantial risk of morbidity and mortality associated
with allogeneic BMT has so far prevented its application
in the treatment of patients with severe autoimmune
disease. In contrast, the lower risks of autologous trans-
plants justified trying this approach in patients with
severe autoimmune disease who were refractory to
current treatments. Additional justification came from the
reports [7] that revealed a very poor life expectancy of
subgroups of patients with progressive refractory
rheumatic disease. Furthermore, lymphoablation and mye-
loablation, followed by rescue with haematopoietic stem
cells seemed a rational way to intensify the treatment with
pulsed doses of cyclophosphamide that were under
clinical investigation.
The treatment protocols of the current clinical studies on
autologous BMT are based essentially on our findings in
the two models of induced autoimmune diseases: AA and
EAE (see below). These models have much in common
with regard to the responses to treatment, but there are
also considerable differences. In translating these results
to the clinic, one can choose to adhere strictly to the
disease specificities (eg apply the results of the AA model
to treatment strategies for RA and SLE; and those
obtained with EAE to treatment strategies for multiple
sclerosis). This approach suffers from the restrictions
imposed by the imperfections of the models. The other
way to look at the results is to select from each model the
parameters that appear to be most decisive for the
outcome and to apply these to all clinical protocols until
experience shows otherwise.
Outcome of treatment of fully developed
autoimmune diseases with autologous BMT
Both AA and EAE were induced in rats of the inbred
Buffalo strain. These animals develop a chronic progres-
sive systemic arthritis and a chronic remitting/relapsing
encephalomyelitis, respectively. In both diseases high-
dose TBI (9–10 Gy) induces responses in all animals [6••].
In AA 70% are complete responders and 30% are partial
responders. Both spontaneous and induced relapses are
extremely rare in AA after high-dose TBI, but do occur
after conditioning with cyclophosphamide [8•]
Rats with clinical EAE, as manifested by limb paralysis
and/or paresis, respond to autologous BMT with a rapid
complete regression of the neurological symptoms, but one
or more spontaneous relapses occur in 30% [9••]. Reimmu-
nization at the time that most animals have recovered from
their last spontaneous relapse reinduces disease in 70% of
the animals. When syngeneic rather than autologous bone
marrow is used in EAE, the spontaneous relapse rate is the
same [10], indicating that these relapses are initiated by
autoimmune cells that survived conditioning. Accordingly,
T-cell depletion of the graft does not diminish the sponta-
neous relapse rate. This does not imply that the composition
of the autologous graft, especially of the lymphocyte sub-
populations, is irrelevant. On the contrary, after the addition
of autologous spleen cells to the bone marrow graft, the
spontaneous relapse rate of EAE rose to over 90%. Further-
more, the T-cell content of bone marrow grafts of rats is 10
times less than that of human bone marrow grafts.
In both models, the best results have been obtained with
the strongest lymphoablative/myeloablative regimens (ie
supralethal doses of TBI or a combination of a lower TBI
dose and cyclophosphamide). Irradiation of the affected
tissues only (the central nervous system in the case of
EAE, and the legs in the case of AA), or shielding of those
tissues with irradiation of the rest of the body resulted athttp://arthritis-research.com/content/2/4/281
best in limited and temporary remissions [6••,10]. Fraction-
ated TBI was studied in the AA model and proved to be as
effective as single-dose TBI, provided that the total dose
was properly adjusted upwards [8•].
In both AA and EAE, conditioning with cyclophosphamide
alone or busulfan alone at highest tolerated doses was
clearly inferior to TBI. A combination of cyclophosphamide
and busulfan was only slightly less effective than high-
dose TBI. The combination of a lower dose of TBI (4 Gy)
with cyclophosphamide (2×60mg/kg) was as effective as
the highest dose of TBI [8•]. The noteworthy features of
cyclophosphamide as the sole conditioning agent in AA
were not only the lower rate of complete remissions, but
also the substantial incidence (36%) of spontaneous
relapses. In contrast, among 155 AA animals treated with
high-dose TBI or the combination regimens, only one
relapse occurred.
Clinical relevance
The impressive results obtained with high-dose lympho-
ablative/myeloablative conditioning regimens are in accor-
dance with the current concept that autoimmune diseases
are maintained by activated T cells. These have to be inac-
tivated or eliminated as much as possible in order to
achieve complete and lasting remission. The animal experi-
ments are equivocal in demonstrating that treatment with
lower doses of the various cytotoxic agents results in
incomplete responses and more relapses. It is therefore
unlikely that so-called nonmyeloablative conditioning will
be useful, unless the degree of T-cell ablation achieved
can match that of current myeloablative regimens. It is
obvious that the more vigorous ablation carries a higher
risk of treatment-related morbidity and mortality. The
optimal regimen needs to be defined in the clinic for each
category of autoimmune disease.
The finding that cyclophosphamide as the sole condition-
ing agent is less effective than high-dose TBI or the com-
bination regimens implies that less lymphoreduction is
achieved with cyclophosphamide. Many clinical teams
prefer the use of cyclophosphamide alone or combined
with antilymphocyte globulin for conditioning. TBI is not
favoured, mainly because it increases the risk of cancer.
However, cyclophosphamide is an alkylating agent and is
therefore carcinogenic, as is prolonged treatment with
high-dose immunosuppressive agents (for review [11]).
How can the excellent results with autologous stem cells
in animal models and the encouraging preliminary results
with this modality in patients be explained? The current
hypothesis is that the reconstitution of the immune system
from a few haematopoietic stem cells represents a recapit-
ulation of ontogenesis, with the acquisition of self-toler-
ance. This theory is based mainly on the experience with
grafting of purified allogeneic stem cells, which may lead
to full reconstitution of the immunological system in the
absence of graft-versus-host disease.
The most intensive conditioning gives the best results
because it eliminates the highest proportion of autoreac-
tive T lymphocytes. It stands to reason that this effect will
be undone if T cells in the autograft outnumber those sur-
viving in the patient. A rough estimate of the surviving frac-
tions is available only for TBI, and is between 0.1 and
0.01% for the most effective dose (ie 9–10 Gy) [11].
Because of these uncertainties it seemed prudent to
begin clinical studies with maximally depleted autografts.
The recommendation to graft no more that 105 T cells/kg
[12] was based on the capabilities of current CD34 cell
selection techniques. However, these also remove B cells,
natural killer cells and macrophages, which is unnecessary
and possibly harmful. Such rigorous depletion may result
in a prolonged period of severe immunosuppression with
risks of infections and lymphoproliferative malignancies.
Data from the most sensitive model (EAE) suggest that
2×10 6 T cell/kg would still be safe, and this level can be
achieved by specific depletion methodology.
Finally, there is the option of using allogeneic stem cells,
which in the EAE rat minimizes relapses due to its graft-
versus-autologous T-cell effect [13]. Considering the
higher risks of transplantation-associated mortality, the
clinical exploration of allogeneic BMT should be post-
poned until it becomes clear from ongoing studies with
autologous stem-cell transplants which patients might
benefit. For the treatment of connective tissue type
autoimmune diseases, allogeneic stem cells cannot be
recommended because graft-versus-host reactions are
very difficult to distinguish from lesions due to the original
autoimmune disease. It has been suggested that the
induction of mixed allogeneic chimerism might be an
attractive option, by virtue of a graft-versus-host autoimmu-
nity effect in the absence of toxicity and graft-versus-host
disease. Apart from the problem that such induction is as
yet far from standardized, our results with mixed chimeras
in EAE revealed a very high incidence of relapses [14].
For the time being it seems that the available animal
models have been rather exhaustively employed for gener-
ating the essential preclinical data [15]. They are not suit-
able to sort out more subtle details for the optimization of
treatment. The large variety of autoimmune diseases and
the variation of disease manifestations within each disease
cannot be imitated in much detail in the laboratory. If the
accumulated clinical experience with autologous stem-cell
transplants identifies specific fundamental questions, the
animal models might again become useful.
Conclusion
The results of treatment with autologous BMT of the active
inflammatory stages of EAE as well as of AA show that thehighest response rate and the lowest relapse incidence
are achieved using the strongest lympho-myeloablative
conditioning regimens. A similar approach for treating
patients with refractory severe progressive autoimmune
diseases is justified in view of the relatively low
transplantation-related mortality of <5% as observed in
leukaemic and aplastic patients who receive autologous
BMT. This risk may well outweigh the mortality and the
deterioration of quality-of-life associated with ineffective
treatments. Ongoing clinical studies will establish the effi-
cacy of autologous BMT, and accordingly the value of the
animal models in preclinical research.
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